Culture Medium Contains A Growth Factor Or Growth Regulator Patents (Class 435/384)
-
Patent number: 8815597Abstract: The present invention provides a baglike container for centrifugation that is mounted in a centrifuge to thereby allow centrifugation of a dispersion liquid accommodated therein. The baglike container for centrifugation is less likely to tear or break as a result of centrifugation by disposing a container wall surface of the baglike container so as to apply centrifugal force perpendicular to the container wall surface.Type: GrantFiled: August 23, 2007Date of Patent: August 26, 2014Assignee: Takara Bio Inc.Inventors: Hideto Chono, Junichi Mineno, Kazutoh Takesako, Takao Yoshida, Takashi Morimura, Kenji Sakai, Shin-ichi Yamada, Noritsugu Yabe, Yuko Taguchi
-
Patent number: 8802436Abstract: The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.Type: GrantFiled: February 7, 2014Date of Patent: August 12, 2014Assignee: ACell, Inc.Inventors: Kimberly A. Kentner, Katherine A. Stuart, Abram D. Janis
-
Patent number: 8802434Abstract: The protein NM23 is disclosed as an agent for the maintenance of undifferentiated biological cells in culture. The NM23 protein may act as a survival factor for such cultured cells, or to prevent the differentiation and maturation of the cultured cells. The use of NM23 protein is applicable to culture of stem and/or progenitor cells, and particularly to such cells cultured and adapted for therapeutic use. The invention provides methods, media and media supplements for use in the culture of biological cells, and further provides methods of preparing biological cells for therapeutic use, as well as methods of therapy utilising biological cells and medicaments comprising biological cells adapted for therapeutic use.Type: GrantFiled: November 16, 2004Date of Patent: August 12, 2014Assignee: The University of BirminghamInventor: Christopher Martin Bunce
-
Patent number: 8795530Abstract: The present invention relates to methods and systems for optimization of dilution of a viscous starting material to isolate and/or concentrate the product of interest from the starting source material such that the process minimizes the volume of diluent and the total volume of the waste stream generated during the process as well as maximizing the yield of desired product. The system employs cross-flow filtration modules with sub-channels that are equidistant to the inlet and outlet of said modules and such modules are characterized by optimal channel height, optimal transmembrane pressure, etc., which are selected in order to achieve the best combination of product quality and production yield.Type: GrantFiled: January 21, 2010Date of Patent: August 5, 2014Assignee: Smartflow Technologies, Inc.Inventors: Henry B. Kopf, James A. Kacmar
-
Patent number: 8785197Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.Type: GrantFiled: September 27, 2013Date of Patent: July 22, 2014Assignee: CorMatrix Cardiovascular, Inc.Inventor: Robert G Matheny
-
Patent number: 8785195Abstract: A microfiber showing improved mechanical strength, which comprises a micro gel fiber consisting of collagen gel or the like covered with high strength hydrogel such as alginate gel.Type: GrantFiled: October 12, 2010Date of Patent: July 22, 2014Assignee: The University of TokyoInventors: Shoji Takeuchi, Hiroaki Onoe, Yukiko Matsunaga, Daisuke Kiriya, Riho Gojo, Midori Negishi
-
Patent number: 8785194Abstract: The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.Type: GrantFiled: May 8, 2009Date of Patent: July 22, 2014Assignee: Life Technologies CorporationInventors: Stephen Gorfien, Richard Fike, Glenn Godwin, Joyce Dzimian, David A. Epstein, Dale Gruber, Don McClure, Paul Price
-
Patent number: 8785198Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.Type: GrantFiled: September 27, 2013Date of Patent: July 22, 2014Assignee: CorMatrix Cardiovascular, Inc.Inventor: Robert G Matheny
-
Patent number: 8772028Abstract: Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described The human progenitor T cells have the phenotype CD34+CD7+CD1a?CD5? or CD34+CD7+CD1a?CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells b\ coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4) Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.Type: GrantFiled: November 6, 2009Date of Patent: July 8, 2014Assignee: Sunnybrook Health Sciences CentreInventors: Juan Carlos Zuniga-Pflucker, Geneve Awong, Ross La Motte-Mohs
-
Patent number: 8765470Abstract: Methods and composition for providing induced pluripotent stem (iPS) cells are provided. For example, in certain aspects methods including reprogramming B lymphocytes transformed by episomal vectors such as Epstein-Barr virus-based vectors are described. Furthermore, the invention provides induced pluripotent stem cells essentially free of exogenous elements and having B cell immunoglobin variable region rearrangement.Type: GrantFiled: August 3, 2011Date of Patent: July 1, 2014Assignee: Cellular Dynamics International, Inc.Inventors: James Thomson, Deepika Rajesh, Sarah Jane Dickerson, Amanda Mack, Michael Miller
-
Publication number: 20140170693Abstract: Described herein are cell culture media, kits and methods for preparing cell culture media, and methods for culturing cells, for example, cells of the female reproductive tract, and tumor cells.Type: ApplicationFiled: March 23, 2012Publication date: June 19, 2014Applicants: BRIGHAM AND WOMEN'S HOSPITAL, INC., WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventor: Tan A. Ince
-
Patent number: 8753885Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.Type: GrantFiled: January 2, 2013Date of Patent: June 17, 2014Assignee: CorMatrix Cardiovascular, IncInventor: Robert G Matheny
-
Patent number: 8753886Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.Type: GrantFiled: May 1, 2013Date of Patent: June 17, 2014Assignee: CorMatrix Cardiovascular, Inc.Inventor: Robert G Matheny
-
Patent number: 8748176Abstract: Choroid plexus epithelial cells are generated in a culture medium using embryonic stem cells and adding an effective amount of bone morphogenetic protein and/or other members of the transforming growth factor beta (TGF-beta) superfamily. Generation of such choroid plexus epithelial cells are confirmed using a combination of genetic markers, antibodies, histology inspection, functional assays, and integration into the endogenous choroid plexus in mice.Type: GrantFiled: February 9, 2012Date of Patent: June 10, 2014Assignee: The Regents of the University of CaliforniaInventors: Edwin S. Monuki, Momoko Watanabe
-
Patent number: 8741644Abstract: The present invention relates to a method for producing human mast cells from human pluripotent stem cells. More particularly, the present invention provides a method for producing human mast cells from human pluripotent stem cells, comprising the steps of: (a) culturing human pluripotent stem cells under a condition suitable for promoting differentiation of the human pluripotent stem cells into hematopoietic progenitor cells expressing CD34; and (b) culturing the cells obtained in step (a) in the presence of hematopoietic factors comprising thrombopoietin (TPO) and Flt3 ligand.Type: GrantFiled: September 8, 2010Date of Patent: June 3, 2014Assignee: Kyoto UniversityInventors: Tatsutoshi Nakahata, Kohichiro Tsuji, Feng Ma
-
Patent number: 8735155Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.Type: GrantFiled: September 27, 2013Date of Patent: May 27, 2014Assignee: CorMatrix Cardiovascular, Inc.Inventor: Robert G Matheny
-
Patent number: 8735149Abstract: Provided is a method for directing differentiation of neural progenitors with a caudal and ventral specification into motor neurons including culturing neural progenitors in a culturing medium including a basic medium supplemented by at least one inhibitor of the Notch signaling pathway whereby the neural progenitors differentiate into postmitotic motor neurons. The resulting motor neurons may be used for drug development, as carriers, e.g. for gene therapy of protein delivery as well as for transplantation for the purpose of treating a motor neuron disease.Type: GrantFiled: April 5, 2009Date of Patent: May 27, 2014Assignee: Hadasit Medical Research Services & Development LimitedInventors: Benjamin Reubinoff, Etti Ben Shushan, Michal Aharonowiz
-
Patent number: 8728815Abstract: This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.Type: GrantFiled: June 5, 2012Date of Patent: May 20, 2014Assignee: University of Southern CaliforniaInventor: Valter Longo
-
Patent number: 8728814Abstract: Disclosed is an agent for improving at least one activity selected from the group consisting of the growth activity, adhesion activity and extension activity of mesenchymal stem cells, which comprises laminin-5 as an active ingredient. A method of culturing mesenchymal stem cells; a method of isolating mesenchymal stem cells; and a medium, vessel or sheet for use in culturing mesenchymal stem cells are also provided.Type: GrantFiled: August 17, 2006Date of Patent: May 20, 2014Assignee: Oriental Yeast Co., Ltd.Inventors: Kaoru Miyazaki, Junko Hashimoto, Yoshinobu Kariya
-
Patent number: 8728816Abstract: The present invention relates to a medium for the cultivation of eukaryotic cells, the medium comprising as (an) additive(s) DMSO, N-acetylmannosamine (NAcMan), N-acetylglucosamine (NAcGlc), or any combination of two or more of these additives, including the combination of NAcMan and NAcGlc.Type: GrantFiled: November 19, 2010Date of Patent: May 20, 2014Assignee: Lek Pharmaceuticals D.D.Inventor: Tanja Ficko Trcek
-
Patent number: 8697139Abstract: Harvesting articular chondrocyte cells from a non-critical location of a patient and growing additional cells for transplantation into a damaged or diseased disc of the patient.Type: GrantFiled: September 21, 2004Date of Patent: April 15, 2014Inventor: Frank Martin Phillips
-
Patent number: 8685726Abstract: The present invention relates to compositions and methods for maintaining undifferentiated pluripotent stem cell cultures.Type: GrantFiled: April 27, 2010Date of Patent: April 1, 2014Assignee: Viacyte, Inc.Inventors: Thomas C Schulz, Allan J Robins
-
Publication number: 20140086882Abstract: The present invention relates to a method of preparing cells and in particular to a method of preparing breastmilk stem cells (BSCs) by isolation from breastmilk and subsequent culture. The invention further relates to BSCs prepared by the methods of the invention and to methods and uses thereof. The invention has been developed primarily as a method for preparing and culturing BSC.Type: ApplicationFiled: April 19, 2013Publication date: March 27, 2014Applicant: Medela Holding AGInventor: Foteini Hassiotou
-
Patent number: 8673318Abstract: The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.Type: GrantFiled: November 29, 2012Date of Patent: March 18, 2014Assignee: Bavarian Nordic A/SInventors: Ingmar Rathe, Eva Felder, Karl Heller
-
Patent number: 8652846Abstract: The invention provides an apoptosis-modulating cell-free composition comprising conditioned extracellular medium of a stem cell and uses thereof, particularly therapeutic uses. Also provided is a method of obtaining such a composition and an in vitro method of modulating apoptosis.Type: GrantFiled: October 2, 2009Date of Patent: February 18, 2014Assignee: Omnicyte LimitedInventors: Nagy A. Habib, Myrtle Gordon
-
Patent number: 8647872Abstract: An embryonic stem cell line derived from a nucleus-transferred oocyte prepared by transferring a nucleus of a human somatic cell into an enucleated human oocyte may differentiate into various desired cell types.Type: GrantFiled: December 9, 2011Date of Patent: February 11, 2014Assignee: H. Bion Co., Ltd.Inventors: Sung-Il Roh, Woo-Suk Hwang, Byeong-Chun Lee, Sung-Keun Kang, Young-June Ryu, Eu-Gene Lee, Soon-Woong Kim, Dae-Kee Kwon, Hee-Sun Kwon, Ja-Min Koo, Eul-Soon Park, Youn-Young Hwang, Hyun-Soo Yoon, Jong-Hyuk Park, Sun-Jong Kim
-
Patent number: 8642333Abstract: The present invention provides a vehicle for delivering various chemicals, compositions and proteins to stem cells and embryoid bodies. The vehicle may be biocompatible and biodegradable polymer microparticles. Typically the particles will contain at least a growth factor for delivery to the embryoid bodies, and generally the growth factor induces differentiation of the cells in the embryoid body along a specific lineage. The present invention also provides methods for directing differentiation of the cells in the embryoid body.Type: GrantFiled: February 4, 2009Date of Patent: February 4, 2014Assignees: Massachusetts Institute of Technology, Children's Hospital BostonInventors: Lino da Silva Ferreira, Daniel Kohane, Robert Langer
-
Patent number: 8642335Abstract: Compositions of purified biologically active Wnt proteins are provided. Wnt proteins are found to be hydrophobic and post-translationally modified by addition of a lipid moiety at a conserved cysteine residue. Methods for isolation of Wnt utilize detergents that maintain the solubility of the modified protein.Type: GrantFiled: June 8, 2009Date of Patent: February 4, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Roeland Nusse, Karl H. Willert
-
Patent number: 8642334Abstract: The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hESCs for obtaining midbrain dopamine (DA) neurons, motorneurons, and sensory neurons. Further, neural plate tissue obtained using methods of the present inventions are contemplated for use in co-cultures with other tissues as inducers for shifting differentiation pathways, i.e. patterning.Type: GrantFiled: February 17, 2010Date of Patent: February 4, 2014Assignee: Memorial Sloan Kettering Cancer CenterInventors: Stuart Chambers, Lorenz Studer
-
Patent number: 8628963Abstract: The present invention relates to a medium composition comprising neuropeptide Y, effective for proliferation and maintenance of undifferentiated pluripotent stem cells, and a method for culturing undifferentiated pluripotent stem cells using the same. The present invention improves the culture conditions for undifferentiated pluripotent stem cells, and ultimately, the present invention can be effectively used for the development of large-scale culture systems, thereby acquiring clinically applicable pluripotent stem cells. Further, the present invention relates to a dedifferentiation medium composition comprising neuropeptide Y (NPY), and a method for inducing dedifferentiation (or reprogramming) using the same. The present invention improves the culture conditions for dedifferentiation and contributes to develop technology of producing clinically applicable induced pluripotent stem cells, thereby being used for the development of stem cell therapy.Type: GrantFiled: June 16, 2010Date of Patent: January 14, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Yee Sook Cho, Mi-Young Son
-
Patent number: 8628962Abstract: Methods for differentiating stem cells are disclosed herein. These methods can be used to generate neurons, including, but not limited to, dopaminergic neurons. The disclosed methods include culturing stem cells in the absence of fibroblast growth factor-2 to generate embryoid bodies and culturing the embryoid bodies in the presence of an effective amount of at least one of stromal cell-derived factor 1, pleiotrophin, insulin-like growth factor 2, and ephrin B1 on an extracellular matrix for a period of time sufficient to produce dopaminergic neuronal cells. The differentiated cells can be used to study pharmaceutical agents that affect dopaminergic neurons and can be used in the treatment of neurodegenerative disorders such as Parkinson's disease.Type: GrantFiled: November 18, 2009Date of Patent: January 14, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: William J. Freed, Tandis Vazin
-
Publication number: 20140004556Abstract: Methods, compositions and kits are provided for generating inner ear cells in vitro. These methods find use a number of applications, such as in preparing inner ear cells for in vitro screening for agents that are toxic to inner ear cells, for in vitro screening for agents that prevent against, mitigate, or reverse the toxic effects of such agents, and for in vitro screening for agents that promote otoregeneration.Type: ApplicationFiled: January 23, 2012Publication date: January 2, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Stefan Heller, Mohammad Ronaghi, Kazuo Oshima
-
Patent number: 8617887Abstract: The present invention is generally in the field of neurological diseases and disorders, particular in the field of neurodegenerative diseases in which the myelin cover of nerves is lost. IL6R/IL6 chimera is used to promote the formation of oligodendrocytes from embryonic stem cells for treatment of neurodegenerative diseases or posttraumatic nerve damage.Type: GrantFiled: June 13, 2004Date of Patent: December 31, 2013Assignee: Yeda Research and Development Co. LtdInventors: Michel Revel, Peter Lonai, Rozemari Stirbu Lonai
-
Publication number: 20130337562Abstract: Methods for culturing undifferentiated mammalian cells, such as stem and progenitor cells, are provided. The methods involve incubating the cell in the presence of a sustained release composition containing at least one growth factor, wherein the sustained release composition continuously releases the growth factor(s), and wherein the presence of the sustained level of growth factor maintains the cell in an undifferentiated state.Type: ApplicationFiled: June 12, 2013Publication date: December 19, 2013Applicant: Regenerative Research FoundationInventors: Jeffrey Stern, Sally Temple Stern
-
Patent number: 8609414Abstract: The present invention describes stem cells and progenitor cells derived from hemangiomas, including testing of angiogenic inhibitors using these cells. The invention as described is useful in providing a process to culture and propagate hemangioma stem cells and generate xenograft models to develop treatments for infantile hemangiomas and other types of vascular lesions.Type: GrantFiled: June 23, 2011Date of Patent: December 17, 2013Inventors: Yupo Ma, Louis M. Fink, David C. Ward, Milton Waner
-
Patent number: 8597947Abstract: The present application discloses methods expanding SCs in an undifferentiated state, the methods comprising incubating undifferentiated SCs in suspension within a culture system comprising basic medium and knockout serum replacement (KOSR). The methods may also be applicable for selective spontaneous or directed differentiation of SCs into a selected population of somatic cells from a culture system of SCs in suspension, the method further comprising incubating said undifferentiated SCs in culture system that support respectively, spontaneous or directed differentiation of SCs into the selected population of somatic cells. The present application also discloses a culture system for expansion of stem cells (SCs) comprising a suspension of undifferentiated stem cells within basic medium and knockout serum replacement (KOSR). The methods and culture system of the invention may be used for large scale production of differentiated cells.Type: GrantFiled: April 2, 2007Date of Patent: December 3, 2013Assignee: Hadasit Medical Research Services & Development LimitedInventor: Benjamin Reubinoff
-
Publication number: 20130280801Abstract: Disclosed herein are flowable tissue matrix compositions comprising small pieces of partially or completely decellularized tissue suspended in a gelatinized tissue or gelatin gel comprising partially or completely decellularized tissue or synthetic gelatin. The flowable tissue matrix compositions can contain factors that promote or enhance native cell migration, proliferation, and/or revascularization after implantation into a subject. Also disclosed are methods of making and using the flowable tissue matrix compositions. The compositions can be implanted into a tissue in need of repair, regeneration, healing, treatment, and/or alteration, and can promote or enhance native cell migration, proliferation, and/or revascularization.Type: ApplicationFiled: April 23, 2013Publication date: October 24, 2013Applicant: LifeCell CorporationInventor: Wenquan Sun
-
Patent number: 8563309Abstract: The present invention provides a method of producing a cell mass capable of serving as a primitive organ-like structure comprised of a plurality of somatic cell types of somatic origin, comprising: preparing cultures containing the plurality of types of somatic cells; mixing the plurality of types of somatic cell cultures followed by adding a Wnt signal activator to the mixed cell culture; subjecting the culture containing the Wnt signal activator to non-plate contact culturing over a predetermined time period; and replacing the medium of the culture cultured by the non-plate contact culturing with medium not containing Wnt signal activator and further culturing for a predetermined time period; wherein, at least one type of the plurality of somatic cells is maintained in an undifferentiated state.Type: GrantFiled: June 27, 2007Date of Patent: October 22, 2013Assignee: Shiseido Company, Ltd.Inventors: Shigeyoshi Fujiwara, Jiro Kishimoto, Tsutomu Soma
-
Patent number: 8563311Abstract: The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.Type: GrantFiled: May 8, 2012Date of Patent: October 22, 2013Assignee: Technion Research & Development Foundation LimitedInventors: Michal Amit, Joseph Itskovitz-Eldor
-
Patent number: 8541234Abstract: Methods of generating and expanding proliferative, multipotent connective tissue progenitor cells from adult stem cells are provided. Also provided are methods of generating functional tendon grafts in vitro and bone, cartilage and connective tissues in vivo using the isolated cell preparation of connective tissue progenitor cells.Type: GrantFiled: June 19, 2012Date of Patent: September 24, 2013Assignee: Technion Research & Development Foundation LimitedInventors: Joseph Itskovitz-Eldor, Shahar Cohen
-
Publication number: 20130244262Abstract: The present invention provides a cardiomyocyte- and/or cardiac progenitor cell-proliferating agent comprising at least one compound selected from the group consisting of: a GSK3? inhibitor, ERK dephosphorylation inhibitor, Raf activator, CaMK2 inhibitor and p38 inhibitor; and a method for proliferating cardiomyocytes and/or cardiac progenitor cells using the agent.Type: ApplicationFiled: November 17, 2011Publication date: September 19, 2013Applicant: KYOTO UNIVERSITYInventors: Jun Yamashita, Hideki Uosaki
-
Patent number: 8535944Abstract: The present application describes a method of culturing, expanding or growing stem or stem-like cells or induced pluripotent stem cells on a surface, including attaching the cells to the surface through a ligand that binds to the surface and the cells.Type: GrantFiled: June 11, 2010Date of Patent: September 17, 2013Assignee: Minerva Biotechnologies CorporationInventor: Cynthia C. Bamdad
-
Patent number: 8530235Abstract: The present invention relates to a method of modulating apoptosis of a granulosa cell. The method includes one or more of the following steps: (i) modulating the concentration and/or activity of BMP-15 and/or BMP-6 that the granulosa cell is exposed to; (ii) modulating activity of a BMP-15 dependent signalling pathway in the granulosa cell; and (iii) modulating activity of a BMP-6 dependent signalling pathway in a granulosa cell.Type: GrantFiled: July 18, 2006Date of Patent: September 10, 2013Assignee: Adelaide Research & Innovation Pty Ltd.Inventors: Robert B. Gilchrist, Jeremy Thompson, Tamer Hussein
-
Patent number: 8524494Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.Type: GrantFiled: August 25, 2009Date of Patent: September 3, 2013Assignee: Histogen, Inc.Inventors: Gail K. Naughton, Frank Ziegler, Mark Baumgartner, Kyle Nickey
-
Patent number: 8524498Abstract: The methods and compositions described herein are based, in part, on the discovery of a stem cell state in human cells that resembles the morphology observed in murine-derived stem cells. Induction of such a state in human stem cells permits an increase in the efficiency of homologous recombination. Thus, the methods and compositions described herein relate to cells and methods for increasing the efficiency of homologous recombination in human stem cells.Type: GrantFiled: June 1, 2010Date of Patent: September 3, 2013Assignee: The General Hospital CorporationInventors: Niels Geijsen, Christa Buecker
-
Patent number: 8518397Abstract: A method of preparing differentiated NK cells by ex vivo expansion includes the steps of; (1) isolating a plurality of CD34+ hematopoietic cells; (2) culturing the cells in a medium, wherein the medium includes an effective amount of a notch ligand and one or more cytokines selected from the group consisting of IL-7, IL-15, SCF, Flt-3, IL-3 and IL-6; and (3) maintaining the cells in culture for a duration of time sufficient to produce NK cells.Type: GrantFiled: August 12, 2010Date of Patent: August 27, 2013Assignee: Case Western Reserve UniversityInventor: Rose C. Beck
-
Patent number: 8492149Abstract: The present invention relates to a method for inducing the differentiation of neural progenitors, neurons, and dopaminergic neurons from human embryonic stem cells with high efficiency, in which neural selection can be performed by the selected media and physical methods. The invention has advantages such as higher efficiency, the effect of lowering cost and time, and maintenance of neural progenitors for a longer period of time, as compared to the known methods for inducing the differentiation into neural progenitors, neurons, and dopaminergic neurons. Accordingly, the method can stably generate cells used for treating Parkinson's disease or other nervous system diseases.Type: GrantFiled: June 5, 2007Date of Patent: July 23, 2013Assignee: JE IL Pharmaceutical Co., Ltd.Inventors: Myung Soo Cho, Myung-Hwa Kim, Young-II Moon, Shin Yong Moon, Sun Kyung Oh, Hee Sun Kim, Dong-Wook Kim
-
Patent number: 8492080Abstract: The disclosure relates to the use of culture media containing thyroid hormones or analogs thereof, and includes methods and uses thereof for embryo culture, embryo production, embryo maturation, improved survival of embryos and improved viability of embryos post cryopreservation.Type: GrantFiled: October 20, 2009Date of Patent: July 23, 2013Assignee: University of GuelphInventors: William Allan King, Fazl A. Ashkar
-
Patent number: 8489337Abstract: Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of germ cells or gametes. Certain embodiments disclosed herein include, but are not limited to, methods of modifying germ cells or gametes, or methods of administering modified germ cells or gametes to at least one biological tissue.Type: GrantFiled: June 24, 2010Date of Patent: July 16, 2013Assignee: The Invention Science Fund I, LLCInventors: Roderick A. Hyde, Edward K. Y. Jung, Lowell L. Wood, Jr.
-
Publication number: 20130177537Abstract: Disclosed are methods for expanding stem cells that use a unique combination of environmental factors and cell culture conditions to produce stem cells having enhanced proliferation and differentiation characteristics. Also disclosed are methods for enhancing the engraftment and/or migratory potential of stem cells for therapeutic uses. Stem cells having unique proliferation, differentiation, migratory and engraftment characteristics are also disclosed.Type: ApplicationFiled: March 6, 2013Publication date: July 11, 2013Applicant: STEMEDICA CELL TECHNOLOGIES, INC.Inventor: Stemedica Cell Technologies, Inc.